M. LeBlanc

发表

Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.

G. Salles, J. Friedberg, L. Rimsza, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.

J. Friedberg, R. Fisher, T. Miller, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108

L. Rimsza, R. Fisher, T. Miller, 2009, Leukemia & lymphoma.

A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.

L. Rimsza, R. Fisher, T. Miller, 2012, Blood.

A Strategy for Full Interrogation of Prognostic Gene Expression Patterns: Exploring the Biology of Diffuse Large B Cell Lymphoma

L. Rimsza, M. Leblanc, J. Unger, 2011, PloS one.

Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.

M. Leblanc, J. Cooper, K. Fu, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base.

J. Crowley, M. Leblanc, R. Livingston, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.

Sonali M. Smith, J. Friedberg, J. Leonard, 2015, Blood.

Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.

L. Staudt, A. Rosenwald, J. Powell, 2004, The New England journal of medicine.

Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.

R. Fisher, T. Miller, M. Leblanc, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma.

Sonali M. Smith, A. LaCasce, J. Friedberg, 2019, Blood.

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

L. Staudt, A. Rosenwald, J. Powell, 2002, The New England journal of medicine.

Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: A study based on SWOG protocol S0420

M. Leblanc, J. Moon, G. Wolf, 2013, Oncology reports.

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.

L. Staudt, A. Rosenwald, J. Powell, 2003, Cancer cell.

Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer?

M. Leblanc, D. Adelstein, M. LeBlanc, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.

Sonali M. Smith, M. Kaminski, J. Friedberg, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma

L. Staudt, A. Rosenwald, Xin Yu, 2003, The Journal of experimental medicine.

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

R. Gascoyne, A. LaCasce, J. Friedberg, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.

J. Crowley, M. Leblanc, R. Livingston, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

M. Kaminski, M. Czuczman, J. Friedberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trends in Medical Aid in Dying in Oregon and Washington

L. Ellis, M. Leblanc, L. Taylor, 2019, JAMA network open.

Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.

M. Leblanc, J. Moon, G. Wolf, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The diffusion of docetaxel in patients with metastatic prostate cancer.

Ruth Etzioni, M. Leblanc, W. Barlow, 2015, Journal of the National Cancer Institute.

The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials.

M. Leblanc, S. Ramsey, W. Barlow, 2016, JAMA oncology.

Association of National Cancer Institute–Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications

M. Leblanc, J. Unger, D. Hershman, 2019, JAMA network open.

Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400

David Wholley, Jeffrey D Bradley, Dana Sparks, 2015, Clinical Cancer Research.

SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Sonali M. Smith, J. Friedberg, J. Leonard, 2020 .

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Meland, L. Staudt, A. Rosenwald, 2002, The New England journal of medicine.

Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.

J. Cooper, K. Fu, W. Sakr, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings

M. Leblanc, S. Ramsey, W. Barlow, 2020, JAMA network open.

The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population

M. Leblanc, J. Unger, C. Blanke, 2017, JAMA oncology.

FDG‐PET/CT–guided intensity modulated head and neck radiotherapy: A pilot investigation

Yoshimi Anzai, Paul Kinahan, Eric C Ford, 2005, Head & neck.

Clinical Trials and Observations

A. Nademanee, R. Fisher, J. Unger, 2008 .

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.

L. Schwartz, M. Leblanc, R. Herbst, 2020, The Lancet. Oncology.

On the design, conduct and lessons learned from Lung-MAP (SWOGS1400): A biomarker-driven master protocol to evaluate biomarker-driventherapies for previously-treated squamous lung cancer

Stacey, L. Schwartz, M. Leblanc, 2021 .

Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder

Alan M. Miller, L. Gordon, R. Fisher, 2008, Transplantation.

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.

R. Fisher, T. Miller, M. Leblanc, 2003, Blood.

Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.

R. Fisher, T. Grogan, T. Miller, 1998, The New England journal of medicine.

Estimated impact of the Prostate Cancer Prevention Trial on population mortality

J. Crowley, M. Leblanc, I. Thompson, 2005, Cancer.

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.

A. Rosenwald, R. Gascoyne, L. Sehn, 2008, Blood.

New treatment options have changed the survival of patients with follicular lymphoma.

R. Fisher, T. Miller, M. Leblanc, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.

Sonali M. Smith, J. Friedberg, R. Fisher, 2018, The Lancet. Haematology.

A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab

M. Kaminski, M. Czuczman, J. Friedberg, 2013, Clinical Cancer Research.

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.

J. Friedberg, J. Winter, L. Rimsza, 2013, The New England journal of medicine.

Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.

Sonali M. Smith, J. Friedberg, J. Leonard, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Medicaid Expansion of the Patient Protection and Affordable Care Act and Participation of Patients With Medicaid in Cancer Clinical Trials.

D. Hershman, R. Vaidya, Hong Xiao, 2023, JAMA oncology.

Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.

Sonali M. Smith, J. Friedberg, J. Leonard, 2019, Blood advances.

RB but not R‐HCVAD is a feasible induction regimen prior to auto‐HCT in frontline MCL: results of SWOG Study S1106

Sonali M. Smith, J. Friedberg, J. Leonard, 2017, British journal of haematology.

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213.

L. Rimsza, R. Fisher, T. Miller, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetic polymorphisms in oxidative stress‐related genes are associated with outcomes following treatment for aggressive B‐cell non‐Hodgkin lymphoma

J. Cerhan, L. Rimsza, R. Fisher, 2014, American journal of hematology.

SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool.

A. Alizadeh, Sonali M. Smith, J. Friedberg, 2021, Journal of geriatric oncology.

Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816

Sonali M. Smith, J. Friedberg, J. Leonard, 2020, Leukemia & lymphoma.

Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313)

J. Friedberg, R. Fisher, T. Miller, 2008 .

[Radiotherapy of breast cancer].

I. Barillot, M. Leblanc, M. Bollet, 2002, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).

Sonali M. Smith, J. Friedberg, L. Rimsza, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.

L. Staudt, A. Rosenwald, W. Chan, 2004, Blood.

Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease.

R. Fisher, T. Grogan, T. Miller, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.

J. Friedberg, J. Leonard, B. Cheson, 2020 .

Phase II trial of R‐CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601

Sonali M. Smith, J. Friedberg, L. Rimsza, 2016, British journal of haematology.

SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).

Sonali M. Smith, J. Friedberg, J. Leonard, 2023, Journal of Clinical Oncology.

Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort

Sonali M. Smith, J. Friedberg, J. Leonard, 2018, Haematologica.

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.

J. Cerhan, J. Friedberg, T. Habermann, 2015, Blood.

Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.

L. Rimsza, R. Fisher, R. Braziel, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

Sonali M. Smith, J. Friedberg, C. Flowers, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study

Sonali M. Smith, J. Friedberg, J. Leonard, 2017 .

The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial.

A. Nademanee, R. Fisher, M. Leblanc, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520

Sonali M. Smith, J. Friedberg, L. Rimsza, 2016, Leukemia & lymphoma.

Clinical Significance of MYC Expression and/or “High-grade” Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas: A SWOG S9704 Correlative Study

L. Rimsza, R. Fisher, M. Leblanc, 2014, The American journal of surgical pathology.

Extranodal presentation in limited-stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001

Sonali M. Smith, J. Friedberg, J. Leonard, 2022, Haematologica.

Recommendations for Clinical Trial Development in Mantle Cell Lymphoma

J. Friedberg, J. Leonard, M. Leblanc, 2017, Journal of the National Cancer Institute.

A Multi Center Trial of hyperCVAD+Rituxan in Patients with Newly Diagnosed Mantle Cell Lymphoma.

R. Fisher, T. Miller, M. Leblanc, 2007 .

Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials

Shing M. Lee, M. Leblanc, L. Minasian, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 trial of CHOP chemotherapy followed by tositumomab / iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma : Southwest Oncology Group Protocol S 9911

R. Fisher, T. Miller, M. Leblanc, 2003 .

Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.

L. Rimsza, R. Fisher, T. Miller, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials

M. Leblanc, S. Ramsey, J. Unger, 2016, Cancer Epidemiology, Biomarkers & Prevention.

Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736.

Sonali M. Smith, J. Friedberg, M. Leblanc, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.

J. Friedberg, R. Fisher, T. Miller, 2015, Blood.

PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001

Sonali M. Smith, J. Friedberg, J. Leonard, 2019, Blood.

FDG-PET prediction of head and neck squamous cell cancer outcomes.

M. Leblanc, J. Eary, K. Krohn, 2004, Archives of otolaryngology--head & neck surgery.

Comparison of survival outcomes among cancer patients treated in and out of clinical trials.

Diane P. Martin, Ruth Etzioni, M. Leblanc, 2014, Journal of the National Cancer Institute.

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma

Sonali M. Smith, M. Kaminski, J. Friedberg, 2023, Blood advances.

Outcomes of MYC‐associated lymphomas after R‐CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704

Sonali M. Smith, J. Friedberg, J. Winter, 2016, British journal of haematology.

A phase I/II trial of vorinostat (SAHA) in combination with rituximab‐CHOP in patients with newly diagnosed advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0806

Sonali M. Smith, J. Friedberg, L. Rimsza, 2015, American journal of hematology.

Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.

L. Staudt, A. Rosenwald, W. Chan, 2005, Blood.

Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials.

J. Crowley, P. Catalano, M. Leblanc, 2014, Clinical cancer research : an official journal of the American Association for Cancer Research.

The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials.

M. Leblanc, I. Thompson, P. Goodman, 2017, Cancer epidemiology.

The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies.

M. Leblanc, I. Thompson, C. Coltman, 2004, Urologic oncology.

Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma

L. Rimsza, T. Grogan, T. Miller, 2007, Laboratory Investigation.

Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials

Dawn L. Hershman, Michael LeBlanc, M. Leblanc, 2020, JAMA network open.

Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in stage I, II, and III squamous cell carcinoma of the supraglottic larynx: report of Southwest Oncology Group Phase 2 Trial S9709.

M. Leblanc, W. Sakr, J. Moon, 2007, Archives of otolaryngology--head & neck surgery.

Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder

L. Gordon, R. Fisher, T. Grogan, 2008, Transplantation.

Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618

M. Leblanc, S. Ou, J. Moon, 2011, Investigational New Drugs.

U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881).

J. Friedberg, C. Flowers, R. Fisher, 2014 .

Development and Use of Integral Assays in Clinical Trials

R. Schilsky, M. Leblanc, J. Doroshow, 2012, Clinical Cancer Research.

Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.

R. Fisher, T. Miller, J. Forman, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of R-CHOP Plus Bortezomib Induction Therapy Followed By Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601

J. Friedberg, L. Rimsza, R. Fisher, 2014 .

Effect of Adding Rituximab to Three Cycles of CHOP Plus Invoved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014).

R. Fisher, T. Miller, M. Leblanc, 2004 .

Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).

R. Fisher, T. Grogan, T. Miller, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T‐cell non‐Hodgkin lymphoma

R. Fisher, T. Miller, M. Leblanc, 2013, Cancer.

Proportional hazards and recursive partitioning and amalgamation analyses of the southwest oncology group node-positive adjuvant CMFVP breast cancer data base: a pilot study

Michael LeBlanc, Stephanie Green, M. Leblanc, 2005, Breast Cancer Research and Treatment.

Follicular lymphoma international prognostic index.

A. López-Guillermo, H. Tilly, P. Zinzani, 2004, Blood.

Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic

M. Leblanc, J. Unger, D. Hershman, 2021, JAMA network open.

FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma.

Yoshimi Anzai, Paul Kinahan, Juergen Meyer, 2005, International journal of radiation oncology, biology, physics.

Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis

Sonali M. Smith, J. Friedberg, J. Winter, 2019, Leukemia & lymphoma.

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

L. Rimsza, R. Fisher, T. Miller, 2012, Haematologica.

Umbrella Test the effect of one or more drugs on one or more single mutations in a variety of cancer types Test the impact of different drugs on different mutations in a single type of cancer Basket

L. Schwartz, R. Yelensky, M. Leblanc, 2015 .

New Treatment Options Have Changed the Natural History of Follicular Lymphoma.

R. Fisher, T. Miller, M. Leblanc, 2004 .

Reply to M.C. Chamberlain

J. Friedberg, R. Fisher, T. Miller, 2009 .

Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study.

R. Fisher, T. Grogan, T. Miller, 2001, Journal of Clinical Oncology.

Fcγ Receptor Polymorphisms Do Not Influence Progression Free Survival (PFS) of Follicular NHL Pateints Treated with Chop Followed by Rituximab (SWOG 9800).

R. Fisher, J. Radich, T. Grogan, 2004 .

Sonali M. Smith, M. Kaminski, J. Friedberg, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016

Sonali M. Smith, M. Kaminski, J. Friedberg, 2016 .

A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group.

M. Leblanc, J. Moon, G. Wolf, 2009, Archives of otolaryngology--head & neck surgery.

CLINICAL INVESTIGATION Head and Neck FDG-PET/CT IMAGING FOR PRERADIOTHERAPY STAGING OF HEAD-AND-NECK SQUAMOUS CELL CARCINOMA

Paul Kinahan, M. Leblanc, J. Eary, 2005 .

Comparison of survival outcomes among cancer patients treated in and out of clinical trials.

Diane P. Martin, Ruth Etzioni, S. Ramsey, 2014, Journal of the National Cancer Institute.

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.

D. Scott, Sonali M. Smith, J. Friedberg, 2019, Blood.

Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies

R. Gray, W. Curran, S. Mandrekar, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial.

M. Leblanc, J. Moon, J. Ensley, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

L. Rimsza, R. Fisher, T. Miller, 2012, Blood.